Bayer continues to grow its open innovation activities
- Details
- Category: Bayer
With Grants4Indications™ Bayer has launched its fifth global crowdsourcing initiative. This latest web-based grant program promotes the exploration of new indications with the aim to discover novel potential therapeutic areas for Bayer compounds.
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).
Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening
- Details
- Category: Bristol-Myers Squibb
To mark National Cancer Prevention Month, the Bristol-Myers Squibb Foundation today announced eight grants totaling nearly $11.5 million that will help make lung and skin cancer screening programs, care and patient support more accessible to underserved populations.
Abbott to Acquire Alere, becoming leader in point of care testing
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion.
Merck announces new biopharma heads for North America and China
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's biopharma business in North America and Marc Horn will take the helm of the biopharma business in China.
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable
- Details
- Category: Boehringer Ingelheim
The European Commission (EC) has taken an EU-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicines. This decision follows the opinion of the Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) as well as the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) within the European Medicines Agency (EMA).
More Pharma News ...
- Merck launches Vivera in Latin America
- Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia
- Sanofi Pasteur provides key support to the Human Vaccines Project
- Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
- Shire to combine with Baxalta, creating the global leader in rare diseases
- Pfizer expands R&D equity investment strategy to access early-stage scientific innovations
- AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™